Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus, Sudden-Onset Clear all
Completed Early Phase 1 Interventional

Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop

NCT02135068
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Closed Loop (CL) System, Snacking
Device · Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 44 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Early Phase 1 Interventional Results available

Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes

NCT01856790
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, liraglutide
Device · Drug
Lead sponsor
Jennifer Sherr
Other
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional

Full Day and Night Closed-Loop With DiAs Platform

NCT02147860
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs) with USS Virginia, Sensor Augmented Pump Therapy
Device · Other
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 35 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Stanford, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Early Phase 1 Interventional

Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D

NCT03632759
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Liraglutide, Golimumab
Drug
Lead sponsor
Carla Greenbaum, MD
Other
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Idaho Falls, Idaho • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-Thymocyte Globulin, Cyclosporine, and RAD in Islet Transplantation

NCT00286624
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia
Interventions
Allogeneic Islets of Langerhans, Everolimus, anti-thymocyte globulin, Cyclosporine
Biological · Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2008 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Dapagliflozin Effects on Hypoglycemia

NCT03704818
View directory record Official record
Conditions
Type1 Diabetes Mellitus
Interventions
Dapagliflozin 5mg, Placebo Oral Tablet
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

NCT03740919
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 17 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 16, 2026, 6:24 AM EDT
Completed No phase listed Observational

Patient and Parent Preferences for an On-Body Automated Insulin Delivery System

NCT03534544
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Not listed
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
8 Years to 25 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus

NCT02755064
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Erythromycin lactobionate, Placebo IV, [13C]-Spirulina, Erythromycin Ethylsuccinate Suspension, Placebo Suspension
Drug
Lead sponsor
Adil Bharucha
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 1 Interventional

The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

NCT02002130
View directory record Official record
Conditions
Type I Diabetes
Interventions
Placebo GABA and Placebo GAD-alum, GABA and Placebo GAD-alum, Active Oral GABA and Active GAD-alum injection
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
4 Years to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus

NCT01421355
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Atazanavir
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 16, 2026, 6:24 AM EDT
Completed No phase listed Observational

Collection of Breath and Sweat to Identify Indicators of Hypoglycemia

NCT03600116
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Oct 16, 2026, 6:24 AM EDT
Withdrawn Phase 2 Interventional

Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 Diabetes

NCT01477476
View directory record Official record
Conditions
Type I Diabetes
Interventions
Anakinra, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 16, 2026, 6:24 AM EDT
Active, not recruiting Not applicable Interventional

Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes

NCT05639088
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Transition preparation program, Educational materials
Behavioral · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
16 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

A Performance Evaluation of the Enlite Glucose Sensor to Support a Full 144 Hours(6Days) of Use

NCT01464346
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
Enlite Sensor
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Escondido, California • La Jolla, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 16, 2026, 6:24 AM EDT
Terminated Early Phase 1 Interventional

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

NCT01954459
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insupatch, Continuous glucose sensor
Device
Lead sponsor
Yale University
Other
Eligibility
8 Years to 44 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Medtronic Treat to Range (TTR) Closed-Loop Control

NCT01490151
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Metabolic and Nutritional Disorders
Interventions
TTR controller (Medtronic)
Device
Lead sponsor
Stanford University
Other
Eligibility
15 Years to 30 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2017 · Synced Oct 16, 2026, 6:24 AM EDT
Not listed Not applicable Interventional

Fit-One: A Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes

NCT03459573
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, PreDiabetes
Interventions
One Drop | Experts On Track, One Drop | Experts On Call, One Drop | Experts Revive
Behavioral
Lead sponsor
Chandra Osborn, PhD, MPH
Industry
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes

NCT06141941
View directory record Official record
Conditions
Pregestational Diabetes
Interventions
CGM
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Neural-net Artificial Pancreas (NAP)

NCT05876273
View directory record Official record
Conditions
Type1 Diabetes
Interventions
Neural-net Artificial Pancreas, University of Virginia Model Predictive Control
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2605541 Versus Insulin Glargine on Blood Sugar

NCT01654380
View directory record Official record
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
LY2605541, Insulin glargine
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional Results available

Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas

NCT01161862
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Bi-hormonal (insulin and glucagon) artificial pancreas
Device
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
12 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 16, 2026, 6:24 AM EDT
Completed Not applicable Interventional

A Reinforcement Approach to Increase Use of CGM

NCT02907346
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Reinforcement for wearing CGM
Behavioral
Lead sponsor
Yale University
Other
Eligibility
13 Years to 26 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 16, 2026, 6:24 AM EDT